Industry news that matters to you.  Learn more

OPKO Announces Publication of ProtecT Study Using Kallikrein Biomarkers in 4Kscore Test

OPKO Health, Inc. (NYSE:OPK) recently announced the online publication of a study entitled “Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study” in the Journal of the National Cancer Institute. The study shows that the four kallikrein panel of biomarkers utilized in the OPKO 4KscoreĀ® Test (Total PSA, Free PSA, Intact PSA and hK2) accurately identifies risk for aggressive prostate cancer prior to prostate biopsy.

OPKO Health Enters into License Agreement with International Health Technology for Next Generation Prostate Cancer Biomarker Panel

OPKO Health, Inc. (NYSE:OPK) today announced execution of a license agreement granting International Health Technology, Ltd. (Cambridge, England) the right to offer OPKO’s novel panel of kallikrein biomarkers and associated algorithm for the detection of prostate cancer in a laboratory setting in the U.K., Ireland, Sweden and Denmark. The OPKO panel represents the culmination of a decade of research by scientists in Europe and the U.S. and has been demonstrated in over 10,000 patients to predict the probability of cancer-positive biopsy in men suspect for prostate cancer. Studies have shown use of the panel could eliminate a significant amount of unnecessary prostate biopsies, demonstrating a reduction of over 50%.

OPKO Health Acquires Next Generation Prostate Cancer Tests

OPKO Health, Inc. yesterday announced the acquisition of an exclusive license from Arctic Partners Ab Oy (Turku, Finland) for two biomarkers in the kallikrein family which, used together with prostate specific antigen (PSA), can reduce the need for prostate biopsies by over 50%. These novel biomarkers were developed by investigators at the University of Malmo, Sweden, University of Turku, Finland, and Memorial Sloan Kettering Cancer Center, New York. The research results indicate that these markers can predict initial biopsy results in men suspected of having prostate cancer; they have been tested in over 8,000 men and were independently validated in the European Randomized Study of Prostate Cancer Screening (Rotterdam).